NRXP
NRX Pharmaceuticals, Inc.
Next earnings Aug 17, 2026 · consensus $0.12 EPS, $30.5M rev
$3.73
▲ +4.78%$3.73▲ +14.42%
over 1Y
L $1.68EODHDH $4.62
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+4.8%
1W-4.4%
1M-12.9%
3M+70.3%
YTD+42.4%
1Y+14.4%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 11 analysts
Buy
Conservative balance sheet (liabilities/equity -1.81x); but unprofitable (net margin -2336.5%).
NRX Pharmaceuticals, Inc. shows $1.23M in FY2025 revenue, a -2336.5% net margin.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | $1.23M |
| Gross profit | — | — | — | — | — |
| Operating income | -$116M | -$44.3M | -$27.8M | -$18.5M | -$16.2M |
| Net income | -$93.1M | -$39.8M | -$30.1M | -$25.1M | -$28.6M |
| Diluted EPS | -$1.98 | -$0.60 | — | — | — |
| Net margin | — | — | — | — | -2336.5% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$134M
EV / EBITDA—
EV / Sales109.3
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-23.2%
FCF yield-11.4%
Quality & risk
ROIC (est.)—
Free cash flow-$14.1M
Total debt$18.3M
Net cash-$10.5M
Altman Z-Score-36.46 distress
Piotroski F-Score5/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+95.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-032026-06-04open ↗424B5Filing2026-06-03open ↗8-KPeriod ending 2026-06-022026-06-02open ↗424B5Filing2026-06-02open ↗25-NSEFiling2026-05-22open ↗10-QPeriod ending 2026-03-312026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗8-KPeriod ending 2026-03-232026-03-24open ↗10-KPeriod ending 2025-12-312026-03-23open ↗DEFA14AFiling2026-02-24open ↗ARSPeriod ending 2024-12-312026-02-23open ↗DEF 14APeriod ending 2026-03-232026-02-23open ↗
Frequently asked
- Is NRX Pharmaceuticals, Inc. (NRXP) a buy?
- NRXP currently carries a Avoid rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity -1.81x); but unprofitable (net margin -2336.5%).
- What is NRX Pharmaceuticals, Inc.'s quality score?
- NRXP scores 18.941176470588236/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001719406, latest 10-Q filed 2026-05-15) · EODHD · as of 6/26/2026, 6:13:45 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.